Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer
2020-000076-37Phase 2Active
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in prostate adenocarcinoma, sponsored by Radboud University Medical Center. Primary endpoint: Disease control at predefined timepoint. Started Mar 2023; status: active.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on 2020-000076-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000076-37.